Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...
Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...
Zacks Investment Research on MSN
Why Zoetis (ZTS) is a top momentum stock for the long term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true. However, dividends are paid out of cash flow, not earnings, so a payout ratio ...
As Chair of the Scientific Advisory Committee, Dr. Lewis-Hall will provide leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities, ...
Kyntra Bio Inc. KYNB, formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from ...
In the lucrative obesity drug race, there is Eli Lilly — and then there's everybody else. A pair of headlines Monday ...
The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna, accelerated a revival of Moderna shares that has been in progress over recent months ...
Pfizer's dividend yield is a lofty 6.2%. That's well above the 1.1% yield offered by the S&P 500 index and the 1.7% yield of the average pharmaceutical stock. And the company recently provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results